Research programme: oral anthrax vaccine - Emisphere Technologies/USAMRIID

Drug Profile

Research programme: oral anthrax vaccine - Emisphere Technologies/USAMRIID

Latest Information Update: 17 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emisphere Technologies; United States Army Medical Research Institute of Infectious Diseases
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 08 Aug 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO 2005)
  • 04 Jul 2003 Preclinical trials in Anthrax in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top